Medical Technology
From clearance to commercial scale.
Medtech companies finance development, regulatory pathways, and commercialization in sequence.
How capital moves through a medical technology company
Development and regulatory pathway
Products require clearance or approval before commercial sale.
Read more: Development and regulatory pathway
Medical device and diagnostics companies spend on engineering, testing, and clinical evidence before products can be sold. The regulatory pathway determines how long and how expensive development will be, ranging from relatively short clearance processes to lengthy approvals requiring clinical trials. Regulatory strategy remains with qualified specialists, but financial plans must reflect the realistic timeline and cost of each pathway.
Reimbursement and market access
Adoption depends on whether providers can be paid for using the product.
Read more: Reimbursement and market access
Even after approval, commercial success depends on coding, coverage, and payment by insurers. Without adequate reimbursement, hospitals and physicians may hesitate to adopt a product regardless of clinical value. Building reimbursement evidence can take years. Financial plans should model adoption under realistic reimbursement scenarios, including delays in coverage decisions, rather than assuming immediate uptake after clearance. Payment timelines should be modeled explicitly.
Manufacturing scale-up and gross margin
Unit cost falls with volume, but scale-up requires investment.
Read more: Manufacturing scale-up and gross margin
Early production is often expensive, with low volumes, manual processes, and quality system requirements. Gross margin improves as volume rises and manufacturing matures. Companies may manufacture internally or use contract manufacturers, each with different capital and cost implications. Inventory, including consigned products at hospitals, can tie up significant working capital during commercial launch. Contract manufacturing terms deserve careful review, since minimums and pricing affect both cash and margin.
Funding stages and runway
Capital is raised in stages tied to technical and commercial milestones.
Read more: Funding stages and runway
Medical technology companies typically raise venture capital in rounds aligned with milestones such as design freeze, regulatory clearance, and early commercial traction. Venture debt and grants can supplement equity. Missing milestones can make subsequent rounds harder. Runway planning must account for regulatory and commercial uncertainty and include contingency for delays. Delays should also be expected in planning, and alternative funding sources identified well before cash is needed.
Where medical technology companies feel pressure
Regulatory timeline uncertainty
Delays extend spending without revenue.
Read more: Regulatory timeline uncertainty
Additional testing requests or clinical data requirements can delay clearance or approval by months or years. Spending continues while revenue is deferred. Financial plans with contingency for regulatory delays help boards manage runway and financing timing.
Reimbursement gaps
Approved products may lack adequate payment.
Read more: Reimbursement gaps
Without established coding and coverage, hospitals and physicians may be reluctant to adopt new products. Building reimbursement can require additional studies and time. Commercial forecasts should reflect realistic adoption curves and reimbursement milestones. Early payer engagement can shorten timelines, so its cost and timing belong in the plan from the start.
Unit cost and gross margin
Early margins can be weak.
Read more: Unit cost and gross margin
Low volume production, scrap, and quality costs keep early unit costs high. Investors scrutinize the path to target gross margin. Cost tracking and manufacturing plans that show realistic improvement build credibility with investors and acquirers. Supplier terms also matter.
Commercial build cost
Sales and clinical support teams are expensive.
Read more: Commercial build cost
Launching a device often requires sales representatives and clinical specialists who support procedures. These costs can exceed early revenue substantially. Measuring productivity by territory helps leaders pace commercial investment against adoption. Commercial investment can then be paced against measured adoption in each territory and region.
Consigned and field inventory
Inventory at customer sites ties up cash.
Read more: Consigned and field inventory
Many device companies place inventory at hospitals on consignment, along with instrument sets. This inventory can be large relative to revenue and difficult to track. Accurate inventory management reduces write-offs and protects working capital. Regular reconciliation of field inventory is essential.
Runway and financing timing
Milestones and markets do not always align.
Read more: Runway and financing timing
Financing windows may close just as a company needs capital. Planning runway well beyond the next milestone and identifying cost levers in advance give boards flexibility to adjust without compromising key programs. Contingency plans should be prepared well before they are needed.
Advisory for device and diagnostics companies from development to scale
Finance & Accounting Advisory
Fractional CFO leadership, cost tracking, and investor reporting.
Read more: Finance & Accounting Advisory
Perrin & Co. provides fractional or interim CFO leadership, product cost and inventory tracking, board and investor reporting, and close processes. Work covers finance and operations only and does not include regulatory strategy, clinical, or quality system services.
Business Advisory
Runway, commercialization, and margin planning.
Read more: Business Advisory
Financial decision support models runway against regulatory and reimbursement timelines, evaluates commercial launch investment, and analyzes manufacturing and gross margin plans. Scenarios help boards decide how to pace spending and when to raise capital. Analysis uses realistic timelines.
Capital Structure & Financing
Venture debt and equipment financing as borrower.
Read more: Capital Structure & Financing
Perrin & Co. analyzes venture debt, equipment financing, and grant funding alongside equity alternatives and supports management in lender discussions as borrower. The firm does not raise equity, place securities, or act as placement agent. Terms vary by lender and facility.
Technology Solutions
Systems for inventory, cost, and financial reporting.
Read more: Technology Solutions
Perrin & Co.'s Technology Solutions capability can help implement inventory, costing, and financial reporting systems that track consigned stock and product cost accurately. Work concerns financial systems and excludes quality management or regulatory documentation systems. Reporting accuracy improves as a result.
Where to start
- Finance & Accounting AdvisoryCFO leadership and planning.
- Business AdvisoryCommercialization decisions.
Scope qualification. Perrin & Co. provides financial and operational advisory only. We do not provide clinical, medical coding, reimbursement compliance, regulatory, licensure, or legal advice, and this page does not represent specialized healthcare regulatory credentials. Those matters remain with qualified healthcare counsel and specialists.
More in Healthcare & Life Sciences
Discuss your medical technology priorities
A confidential conversation with Perrin & Co. — no obligation, and a candid view of whether we can help.